BACKGROUND: Several noninvasive risk factors (NIRFs) have been proposed for sudden cardiac death risk stratification in post-myocardial infarction(post-MI) patients with preserved ejection fraction (EF). However, it remains unclear if these factors change over time. Continue reading →

Alexander et al. [1] aimed at examining the association between non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) with risk of incident acute myocardial infarction and stroke using electronic records from four European primary care databases. Unfortunately, the investigators have fallen short from their stated goal Continue reading →

Acutemyocardial infarction(AMI) patients constitute a large proportion of admissions in coronary care unit and their management and risk stratification is of immense importance. A decrease in serum albumin concentration might be associated with an increased risk in the incident of both cardiovascular diseases and worse hospital outcome. We assessed whether serum albumin levels at admission was associated with in-hospital adverse outcome in patients with first attack of acutemyocardial infarction(AMI) Continue reading →

Jaya Mallidi, MD, MHS "If he were your family member, would you still recommend medical therapy first?" the primary care physician asked with genuine concern over our mutual patient, Mr Simon.* I had seen Mr Simon for evaluation of chest pain. He was a sturdy man who lived alone with his dog, Midge Continue reading →

Jon Margolis is VTDiggers political analyst. Not for the first time, Sen Continue reading →

Yes, I could make you feel better. Yes, I realize that I am quite cute. Continue reading →

October 11, 2019 The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at two years of follow-up in a randomized trial against Abbotts Xience stent, according to results presented at Transcatheter Cardiovascular Therapeutics (TCT) 2019, Sept. 25-29 in San Francisco. Patients who got the Supraflex stent in the TALENT trial had 6.9 percent target lesion failure occur at 720 days (versus 7.9% percent of Xience recipients), according to a presentation by Azfar Zaman, M.D., cardiac catheter laboratories, Royal Freeman Hospital, Newcastle, United Kingdom Continue reading →